

Ruentex Industries Ltd.

Summary of the 2025 Annual Board Meeting Minutes

Term /Session	Date of the Meeting	Summary of important proposals and resolutions	Independent directors' opinions
17/07	2025.01.21	<ol style="list-style-type: none"> 1.The progress report of the remuneration Committee Meeting Minutes. 2. Reported on the results of 2024 board performance assessment. 3. The ratio of appropriation of employee remuneration for 2024. 4. The proposal to suggest the amount of year-end performance bonus to be issued for 2024. 5. The proposal to suggest the amount of year-end performance bonus for managers for 2024. 6. The proposal to suggest the amount of year-end performance bonus for the Chairman for 2024. 7. Proposal of the 2024 CPA remuneration. 	None of the independent directors expressed objections.
17/08	2025.03.12	<ol style="list-style-type: none"> 1. Report on the implementation plan for the Company's Sustainable Disclosure Standards. 2. Report on the Company's liability insurance policy(ies) for directors. 3. Renewal of the bank loan facility of the Company. 4. Proposal for the amount of employee remuneration to be appropriated for 2024. 5. The Company's 2024 Consolidated Financial Statement (including individual financial statements), Business Report, and Financial Accounting Reports. 6. Distribution of Earnings for 2024. 7. Proposal to distribute cash from the legal reserve, submitted for discussion 8. Amendment to the Company Corporate Charter (Articles of Incorporation). 9. By-election of two Directors. 10.The Company's proposal to convene the 2025 general shareholders' meeting 11. Proposal for the 2024 Statement of Internal Control System of the Company. 12.Nomination List of Candidates for Directors and Independent Directors 	None of the independent directors expressed objections.
17/09	2025.04.08	<ol style="list-style-type: none"> 1. Renewal of the bank loan facility of the Company. 2. Lifting of the non-compete restrictions on newly elected directors. 3. The Company's proposal to convene the 2025 general shareholders' meeting (add motion) 	None of the independent directors expressed objections.
17/10	2025.05.14	<ol style="list-style-type: none"> 1. Reported on Internal Audit Report for the 2024Q1 2.Report on the implementation plan for the Company's Sustainable Disclosure Standards. 3.Renewal of the bank loan facility of the Company. 4. The Company's Consolidated Financial Report of Q1 of 2025. 	None of the independent directors expressed objections.
17/11	2025.07.01	<ol style="list-style-type: none"> 1. Reported on Internal Audit Report for the 2024Q1 2. Determination of the ex-dividend date and payment date of the Company's cash dividend from legal reserve. 3. Proposed to engage in forward foreign exchange transactions 	None of the independent directors expressed objections.
17/12	2025.08.13	<ol style="list-style-type: none"> 1. Reported on Internal Audit Report for the 2025Q2 2. The progress report of the remuneration Committee Meeting Minutes. 3. Report on the 2025Q2 implementation plan for the Company's 	None of the independent directors expressed

Term /Session	Date of the Meeting	Summary of important proposals and resolutions	Independent directors' opinions
		<p>Sustainable Disclosure Standards.</p> <p>4. The progress report of the Company's greenhouse gas inventory and verification schedule.</p> <p>5. Renewal of the bank loan facility of the Company.</p> <p>6. Proposal to subscribe common stock issued by Tanvex BioPharma for cash capitalization.</p> <p>7. The Company's Consolidated Financial Report of Q2 of 2025.</p> <p>8. Proposal to disposal of the land and factory buildings of the Guanyin Factory in Taoyuan City.</p> <p>9. Amendment to the "Employee Compensation Distribution Method"</p> <p>10. The proposal for the addition to the Company's "Internal Control System" and "Internal Audit Act Enforcement Rules"</p> <p>11. Proposal for the amendments to the Company's "Stock Affairs Units Internal Control System Standards"</p> <p>12. The proposal for the Preparation status of the "2024 Sustainability Report"</p> <p>13. Proposal of remuneration to the Company's 17th term of newly Directors .</p>	objections.
17/13	2025.11.13	<p>1. Reported on Internal Audit Report for the 2025Q3</p> <p>2. Report on the 2025Q3 implementation plan for the Company's Sustainable Disclosure Standards.</p> <p>3. Renewal of the bank loan facility of the Company.</p> <p>4. The Company's Consolidated Financial Report of Q3 of 2025.</p>	None of the independent directors expressed objections.
17/14	2025.12.30	<p>1. Explanation on issues of audit planning linked up with the Company's Financial Statements 2025.</p> <p>2. Report on the Company's regular evaluation of the independence of CPAs</p> <p>3. Report on the implementation of cybersecurity management in 2025.</p> <p>4. Report on the implementation of corporate governance and sustainable development of the Company in 2025.</p> <p>5. Report on the "Enterprise Value Enhancement Program " .</p> <p>6. Renewal of the bank loan facility of the Company.</p> <p>7. Proposal to subscribe common stock issued by Brogent Technologies Inc. for cash capitalization.</p> <p>8. Proposal to subscribe common stock issued by Ruen Chen Investment Holdings Ltd. for cash capitalization.</p> <p>9 The 2026 internal audit program of this Company.</p> <p>8. The proposal for the Company's establishment of "Risk Management Policy and Procedures."</p> <p>9. The proposal for the Company's establishment of "Risk Management Policy and Procedures."</p> <p>10. Amendment to the Company's Principles of Corporate Governance.</p> <p>11. Proposal for the amendments to the Company's "Stock Affairs Units Internal Control System Standards".</p>	None of the independent directors expressed objections.